Characterization of the biochemical and structural phenotypes of four CYP1B1 mutations observed in individuals with primary congenital glaucoma
Authors:
- Ingela JanssonIJIngela Jansson
- John B. SchenkmanJSJohn B. Schenkman
- 1 August 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 18 (8) , 665-676
Abstract
Objective The objective of this study was to examine the biochemical and physical properties of cytochrome P450 1B1 (CYP1B1) mutants, test our hypothesis that primary congenital glaucoma (PCG)-causing mutants have altered metabolic activity, and correlate these to structural changes in the molecule. Methods CYP1B1.1 cDNA was mutated to four forms found in individuals with the PCG phenotype, Y81N, E229K, A330F, and R368H. Expression and stability of the mutant hemoproteins and their ability to metabolize β-estradiol, arachidonic acid, and retinoids, were determined. Alterations in mutant properties were related to structural changes by in silico examination, on the basis of the CYP1A2 crystal structure. Results CYP1B1 mutations strongly affected the stability, ease of heterologous expression, and enzymatic properties of the protein. These were related to the location of the amino acid substitutions in the CYP1B1 structure. Three of the mutations involve residues located on the surface of CYP1B1, Y81N, and E229K near the distal surface, and R368H near the proximal surface. The former two substitutions, Y81N and E229K, caused greatly reduced stability at 4°C. Y81N severely inhibited all substrate turnover, but E229K only inhibited arachidonate turnover and exhibited minimal effect on efficiency of retinoid metabolism and estradiol metabolism. The R368H mutation is relatively conservative, affecting charge-pairing with the deeper-located D374, but it severely inhibited metabolism of all substrates tested, and, like Y81N, expression of the enzyme is less facile than CYP1B1wt. The A330F mutation replaces a small alanine by a bulky phenylalanine in the enzyme active site and had major impact on substrate binding, turnover, uncoupling, and metabolite pattern. Conclusion Consistent with the hypothesis, these PCG-related mutations cause identifiable structural changes negatively impacting CYP1B1 biochemistry and stability.Keywords
This publication has 42 references indexed in Scilit:
- Adaptations for the Oxidation of Polycyclic Aromatic Hydrocarbons Exhibited by the Structure of Human P450 1A2Journal of Biological Chemistry, 2007
- Physiological Significance and Expression of P450s in the Developing EyeDrug Metabolism Reviews, 2006
- Expression patterns of mouse and human CYP orthologs (families 1–4) during development and in different adult tissuesArchives of Biochemistry and Biophysics, 2005
- Genetics and biochemistry of primary congenital glaucomaOphthalmology Clinics of North America, 2003
- Modification of Ocular Defects in Mouse Developmental Glaucoma Models by TyrosinaseScience, 2003
- Effect of two mutations of human CYP1B1, G61E and R469W, on stability and endogenous steroid substrate metabolismPharmacogenetics, 2001
- Roles of Cytochrome P450 in DevelopmentDrug Metabolism and Drug Interactions, 2001
- Multiple CYP1B1 mutations and incomplete penetrance in an inbred population segregating primary congenital glaucoma suggest frequent de novo events and a dominant modifier locusHuman Molecular Genetics, 2000
- Mutations in CYP1B1, the Gene for Cytochrome P4501B1, Are the Predominant Cause of Primary Congenital Glaucoma in Saudi ArabiaThe American Journal of Human Genetics, 1998
- Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21Human Molecular Genetics, 1997